The three draft Guidances recently released by the U.S. Food and Drug Administration on implementation of the Biologics Price Competition and Innovation Act of 2009 focus on how to demonstrate biosimilarity but don’t say much about demonstrating interchangeability. FDA has asked for stakeholder input on biosimilar interchangeability at the agency’s upcoming one-day public hearing on
Monthly Archives: March 2012
Biosimilars: Who’s Who at FDA?
According to several recent presentations by U.S. Food and Drug Administration (FDA) officials, the agency has established three committees charged with discussing and coordinating issues related to biosimilars to ensure consistency in the regulatory approach and guidance to sponsors. While FDA set up this infrastructure some time ago, with the issuance of the Draft Guidances